TrialNature communications2025

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.

Jiayu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.